REVVITY, INC Cost of Revenue
REVVITY, INC (RVTY) reported Cost of Revenue of $341.99 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2018-11-06
- REVVITY, INC cost of revenue for the quarter ending 2018-09-30 was $341.99M, a 19.87% increase year-over-year.
- REVVITY, INC cost of revenue for the quarter ending 2018-07-01 was $363.22M, a 25.53% increase year-over-year.
- REVVITY, INC cost of revenue for the quarter ending 2017-10-01 was $285.31M.
- REVVITY, INC cost of revenue for the quarter ending 2017-07-02 was $289.36M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month |
|---|---|---|---|
| 2018-09-30 | $341.99M 10-Q · filed 2018-11-06 | $705.21M derived: sum of 2 quarters · filed 2018-11-06 | $1.06B 10-Q · filed 2018-11-06 |
| 2018-07-01 | $363.22M 10-Q · filed 2018-08-07 | $714.97M 10-Q · filed 2018-08-07 | |
| 2017-10-01 | $285.31M 10-Q · filed 2018-11-06 | $574.67M derived: sum of 2 quarters · filed 2018-11-06 | $849.03M 10-Q · filed 2018-11-06 |
| 2017-07-02 | $289.36M 10-Q · filed 2018-08-07 | $563.72M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |